• Pune-based startup IntegriMedical has launched a Needle-Free Injection System (N-FIS) that offers nearly painless drug delivery without needles.
  • Backed by regulatory approvals and a 20% stake from Serum Institute of India, N-FIS is gaining traction across India and abroad.

Pune-based startup IntegriMedical has introduced a Needle-Free Injection System (N-FIS), a device designed to make drug administration painless and safer. Founded in 2020 by Sarvesh Mutha, Ankur Naik, Scott McFarland, and Mark Timm, the company aims to address the widespread fear of needles and reduce risks for healthcare workers.

The N-FIS is a spring-powered device that delivers medications through a high-pressure jet, bypassing the need for traditional needles. The device uses a stainless-steel piston mechanism and a disposable cartridge with an ultra-thin orifice, which ensures precise, nearly painless drug delivery. 

According to Sarvesh Mutha, Managing Director of IntegriMedical, “Needle phobia is more than just fear—it can cause patients to skip life-saving treatments.”

Beyond patient comfort, the N-FIS reduces needle-stick injuries for healthcare workers and minimizes cross-contamination risks. It has gained regulatory approvals, including CDSCO, CE, ISO 13485, and MDSAP, and is backed by a US patent. The device was launched in April 2024 following successful trials.

IntegriMedical’s business model focuses on a B2B approach, targeting doctors, clinics, hospitals, and vaccination centers. The technology has been adopted in over 30 cities across India, with around 1,000 doctors using it, treating more than 40,000 patients so far. Notable hospitals like Cloudnine, KEM, Apollo Cradle, and Hiranandani are among the adopters.

The startup has also expanded internationally, with its technology being used in a major pediatric hospital in Hungary. In May 2024, Serum Institute of India, the world’s largest vaccine manufacturer, acquired a 20% stake in IntegriMedical, strengthening its growth prospects.

Looking ahead, IntegriMedical plans to broaden its presence in Tier II and III cities in India and explore new therapeutic areas. The company aims to secure more international approvals and establish partnerships with pharmaceutical firms, aiming for a broader global impact in healthcare.

Edited by Harshajit Sarmah